Search results
Your search for Mattox returned no results
Showing 76 to 90 of 264 results for matter
Showing 76 to 90 of 264 results for matter
Evidence-based recommendations on naloxegol (Moventig) for treating opioid-induced constipation in adults.
This quality standard covers decision making in people aged 16 and over, using health and social care services who may lack capacity to make their own decisions (now or in the future). It aims to support implementation of the aims and principles of the Mental Capacity Act 2005 and relevant Codes of Practice. It is not a substitute for these.
Evidence-based recommendations on erlotinib (Tarceva) and gefitinib (Iressa) for treating non-small-cell lung cancer after chemotherapy in adults.
Holding our meetings in public supports our commitment to having processes in place that are rigorous, open, and transparent.
Holding our meetings in public supports our commitment to having processes in place that are rigorous, open, and transparent.
Nintedanib for treating idiopathic pulmonary fibrosis (TA379)
Evidence-based recommendations on nintedanib (Ofev) for adults with idiopathic pulmonary fibrosis.
Evidence-based recommendations on infliximab (Remicade, Inflectra or Remsima), adalimumab (Humira) and golimumab (Simponi) for treating moderate to severe ulcerative colitis in adults, and on infliximab for treating severe active ulcerative colitis in children and young people of 6–17 years.
Information and benefits about shared decision making. Includes links to patient decision aids.
Brensocatib for treating non-cystic fibrosis bronchiectasis in people 12 years and over [ID6448]
In development Reference number: GID-TA11564 Expected publication date: 08 July 2026
This guideline covers encouraging people to increase the amount they walk or cycle for travel or recreation purposes.
This guideline covers planning and delivering multi-agency services for domestic violence and abuse. It aims to help identify, prevent and reduce domestic violence and abuse among women and men in heterosexual or same-sex relationships, and among young people.
Everolimus for preventing organ rejection in liver transplantation (TA348)
Evidence-based recommendations on everolimus (Certican) for preventing organ rejection in adults having a liver transplant.
Canagliflozin, dapagliflozin and empagliflozin as monotherapies for treating type 2 diabetes (TA390)
Evidence-based recommendations on canagliflozin (Invokana), dapagliflozin (Forxiga) and empagliflozin (Jardiance) as options for treating type 2 diabetes in adults.
Evidence-based recommendations on certolizumab pegol (Cimzia) for treating severe active rheumatoid arthritis in adults who have had a tumour necrosis factor-alpha inhibitor.
Evidence-based recommendations on ruxolitinib (Jakavi). This drug is for adults with disease-related splenomegaly or symptoms caused by primary myelofibrosis (also known as chronic idiopathic myelofibrosis), post polycythaemia vera myelofibrosis or post essential thrombocythaemia myelofibrosis, only if they have intermediate-2 or high-risk disease.